Some factors could explain the lack of efficacy of this approach in most patients, such as the known variable expression of the retinoid X receptors in ACTH-secreting adenomas [29], as well as the occasional expression of COUP-TF1 in these tumors [30, 31], which could antagonize the therapeutic effect of both retinoids. Here, NR2F1 is linked to adenoma.